Genetic testing of familial hypercholesterolemia in a real clinical setting

被引:0
作者
Branislav Vohnout
Dominika Gabcova
Miroslava Huckova
Iwar Klimes
Daniela Gasperikova
Katarina Raslova
机构
[1] Slovak Medical University in Bratislava,Co
[2] Slovak Medical University in Bratislava,ordination Center for Familial Hyperlipidemias
[3] Slovak Academy of Sciences,Institute of Nutrition, FOaZOS
来源
Wiener klinische Wochenschrift | 2016年 / 128卷
关键词
Familial hypercholesterolemia; Molecular genetics; Diagnosis; LDL cholesterol; Apolipoproteins;
D O I
暂无
中图分类号
学科分类号
摘要
Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder characterized by strikingly elevated low-density lipoprotein (LDL) cholesterol levels and premature atherosclerosis. For individuals with a definite or probable diagnosis of FH, molecular genetic testing is recommended. This can be justified in countries where genetic testing is broadly available and covered. On the other hand, in countries with limited access to genetic testing, it can be argued whether it is necessary and cost-effective to perform genetic testing in patients with a proven clinical diagnosis of FH. This article presents a family with FH where different family members manifested different phenotypes and discusses situations where genetic diagnosis can crucially help physicians in clinical decision-making on how to approach and treat patients.
引用
收藏
页码:916 / 921
页数:5
相关论文
共 64 条
[1]  
Nordestgaard BG(2013)Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society Eur. Heart J. 34 3478-3490a
[2]  
Chapman MJ(2008)Efficacy of statins in familial hypercholesterolaemia: a long term cohort study BMJ 337 a2423-18
[3]  
Humphries SE(1993)Familial defective apolipoprotein B‑100: a review, including some comparisons with familial hypercholesterolaemia Atherosclerosis 104 1-343
[4]  
Ginsberg HN(2001)Major apolipoprotein B‑100 mutations in lipoprotein metabolism and atherosclerosis Physiol Res 50 337-5
[5]  
Masana L(2003)Lipid levels and their genetic regulation in patients with familial hypercholesterolemia and familial defective apolipoprotein B‑100: the MEDPED Slovakia Project Atheroscler Suppl 4 3-e107
[6]  
Descamps OS(2011)Familial hypercholesterolemia: the lipids or the genes? Nutr Metab (Lond) 8 23-2246
[7]  
Versmissen J(2007)Familial defective apolipoprotein B‑100 in Slovakia: are differences in prevalence of familial defective apolipoprotein B‑100 explained by ethnicity? Atherosclerosis 194 e95-502
[8]  
Oosterveer DM(2006)Diagnosing familial hypercholesterolaemia: the relevance of genetic testing Eur. Heart J. 27 2240-364
[9]  
Yazdanpanah M(1972)Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin. Chem. 18 499-2437
[10]  
Defesche JC(2008)Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: results of a family and DNA-based screening Atherosclerosis 196 356-9